Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review

Area of Science:

• Oncology
• Nanotechnology
• Molecular Biology
• Pharmacology

Background:

• Pancreatic cancer exhibits poor prognosis due to late diagnosis, therapeutic resistance, and limited effective treatments.
• Novel pharmacological strategies are crucial for improving patient survival rates.
• Nanoparticles offer efficient delivery systems for therapeutic agents.

Purpose of the Study:

• To systematically review the literature on nanoparticle-siRNA applications in pancreatic cancer over the last decade.
• To evaluate the effectiveness of combining nanotechnology with small interfering RNA (siRNA) for pancreatic cancer therapy.

Main Methods:

• Systematic literature review conducted across PubMed, Scopus, and Web of Science databases.
• Selection of 37 relevant articles from an initial pool of 164 identified studies.
• Focus on research utilizing nanoparticles loaded with siRNA for pancreatic cancer treatment.

Main Results:

• The combination of nanoparticles and siRNA demonstrates high effectiveness in preclinical and clinical pancreatic cancer models.
• This therapeutic strategy shows potential in overcoming treatment resistance characteristic of pancreatic tumors.
• A significant body of research highlights the efficacy of siRNA-based medicines in this context.

Conclusions:

• Nanoparticle-siRNA conjugates represent a promising new therapeutic strategy for pancreatic cancer.
• This approach holds the potential to revolutionize pancreatic cancer treatment, ushering in a new era of genetic therapies.
• Further development and clinical translation of siRNA-based medicines are warranted.